{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:39:13Z","timestamp":1789893553025,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s11864-014-0320-6","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T04:02:14Z","timestamp":1426046534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Corticosteroids in the Management of Prostate Cancer: A Critical Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Chukwuma","family":"Ndibe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"320_CR1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"320_CR2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"320_CR3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS Bono de","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"320_CR4","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397. This paper reports the results of the pivotal AFFIRM placebo-controlled phase III trial, which demonstrated extension of survival for enzalutamide vs placebo for post-docetaxel men with metastatic castration-resistant prostate cancer. Corticosteroids were not required, but were allowed in both arms.","journal-title":"N Engl J Med"},{"key":"320_CR5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"320_CR6","doi-asserted-by":"crossref","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med. 2014;371:424\u201333. This paper reports the results of the pivotal PREVAIL placebo-controlled phase III trial, which demonstrated extension of survival for enzalutamide vs placebo for docetaxel-na\u00efve men with metastatic castration-resistant prostate cancer. Corticosteroids were not required, but were allowed in both arms.","DOI":"10.1056\/NEJMoa1405095"},{"key":"320_CR7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348. This paper reports the results of the pivotal COU-AA-302 placebo-controlled phase III trial comparing prednisone alone vs prednisone plus abiraterone acetate for docetaxel-na\u00efve men with metastatic castration-resistant prostate cancer. Although prednisone alone showed modest activity, the combination of prednisone and abiraterone acetate extended overall survival.","journal-title":"N Engl J Med"},{"key":"320_CR8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005. This paper reports the results of the pivotal COU-AA-301 placebo-controlled phase III trial comparing prednisone alone vs prednisone plus abiraterone acetate for post-docetaxel men with metastatic castration-resistant prostate cancer. Although prednisone alone showed modest activity, the combination of prednisone and abiraterone acetate extended overall survival.","journal-title":"N Engl J Med"},{"key":"320_CR9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/jnci\/93.22.1739","volume":"93","author":"K Nishimura","year":"2001","unstructured":"Nishimura K, Nonomura N, Satoh E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst. 2001;93:1739\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"320_CR10","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","volume":"7","author":"I Tannock","year":"1989","unstructured":"Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7:590\u20137.","journal-title":"J Clin Oncol"},{"key":"320_CR11","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-05-2085","volume":"12","author":"A Yano","year":"2006","unstructured":"Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006;12:3003\u20139.","journal-title":"Clin Cancer Res"},{"key":"320_CR12","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-06-0749","volume":"12","author":"A Yano","year":"2006","unstructured":"Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006;12:6012\u20137.","journal-title":"Clin Cancer Res"},{"key":"320_CR13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1464-410X.2007.07261.x","volume":"101","author":"R Venkitaraman","year":"2008","unstructured":"Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP, Parker CC. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int. 2008;101:440\u20133.","journal-title":"BJU Int"},{"key":"320_CR14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/1097-0142(19950701)76:1<96::AID-CNCR2820760114>3.0.CO;2-E","volume":"76","author":"JA Storlie","year":"1995","unstructured":"Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer. 1995;76:96\u2013100.","journal-title":"Cancer"},{"key":"320_CR15","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/1097-0142(20001215)89:12<2570::AID-CNCR9>3.0.CO;2-H","volume":"89","author":"K Nishimura","year":"2000","unstructured":"Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000;89:2570\u20136.","journal-title":"Cancer"},{"key":"320_CR16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1046\/j.1442-2042.2001.00302.x","volume":"8","author":"T Saika","year":"2001","unstructured":"Saika T, Kusaka N, Tsushima T, et al. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol. 2001;8:290\u20134.","journal-title":"Int J Urol"},{"key":"320_CR17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0090-4295(98)00149-6","volume":"52","author":"O Sartor","year":"1998","unstructured":"Sartor O, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology. 1998;52:252\u20136.","journal-title":"Urology"},{"key":"320_CR18","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","volume":"17","author":"PW Kantoff","year":"1999","unstructured":"Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506\u201313.","journal-title":"J Clin Oncol"},{"key":"320_CR19","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756\u201364.","journal-title":"J Clin Oncol"},{"key":"320_CR20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1012258723075","volume":"12","author":"TM Beer","year":"2001","unstructured":"Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12:1273\u20139.","journal-title":"Ann Oncol"},{"key":"320_CR21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513\u201320.","journal-title":"N Engl J Med"},{"key":"320_CR22","unstructured":"Health NIH. NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy. Available at: http:\/\/www.nih.gov\/news\/health\/dec2013\/nci-05.htm . Accessed 24 Feb 2014."},{"issue":"Suppl","key":"320_CR23","first-page":"5s","volume":"32","author":"CY-H Sweeney CJ","year":"2014","unstructured":"Sweeney CJ CY-H, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol. 2014;32(Suppl):5s [Abstr act LBA2].","journal-title":"J Clin Oncol"},{"key":"320_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149\u201358.","journal-title":"Lancet Oncol"},{"key":"320_CR25","doi-asserted-by":"crossref","unstructured":"Scher HI HG, Molina GA, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol. 2011;29 (Suppl). [Abstract LBA4517^].","DOI":"10.1200\/jco.2011.29.15_suppl.lba4517"},{"key":"320_CR26","doi-asserted-by":"crossref","unstructured":"De Wit R, Fizazi K, Jinga V, et al. Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). J Clin Oncol. 2014;32(Suppl):5s. [Abstract 5008].","DOI":"10.1200\/jco.2014.32.15_suppl.5008"},{"key":"320_CR27","doi-asserted-by":"crossref","unstructured":"Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015. doi: 10.1200\/JCO.2014.56.5119 .","DOI":"10.1200\/JCO.2014.56.5119"},{"key":"320_CR28","doi-asserted-by":"crossref","unstructured":"Dreicer R Jones R, Oudard S, et al. Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial). J Clin Oncol. 2014;32(Suppl 4). [Abstract 7^].","DOI":"10.1200\/jco.2014.32.4_suppl.7"},{"key":"320_CR29","doi-asserted-by":"crossref","unstructured":"Attard G, Reid AH, de Bono JS. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol. 2010;28:e560\u20131; author reply e2.","DOI":"10.1200\/JCO.2010.29.5170"},{"key":"320_CR30","doi-asserted-by":"crossref","unstructured":"Small EJ, Lance RS, Redfern CH, et al. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer. J Clin Oncol. 2013;31(Suppl). [Abstr 5047^].","DOI":"10.1200\/jco.2013.31.6_suppl.114"},{"key":"320_CR31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700\u201312.","journal-title":"Lancet Oncol"},{"key":"320_CR32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.critrevonc.2013.12.001","volume":"90","author":"CJ Morgan","year":"2014","unstructured":"Morgan CJ, Oh WK, Naik G, Galsky MD, Sonpavde G. Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2014;90:253\u201361.","journal-title":"Crit Rev Oncol Hematol"},{"key":"320_CR33","doi-asserted-by":"crossref","unstructured":"Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29:2191\u20138.","DOI":"10.1200\/JCO.2010.32.8815"},{"key":"320_CR34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2001.19.1.62","volume":"19","author":"SD Fossa","year":"2001","unstructured":"Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001;19:62\u201371.","journal-title":"J Clin Oncol"},{"key":"320_CR35","unstructured":"Higano CS SF, Curti BD, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium; February 26\u201328, 2009. Orlando, FL, USA; 2009. [Abstract LBA150]."},{"key":"320_CR36","unstructured":"Small E, Demkow, T, Gerritsen, WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Proceedings Genitourinary Cancer Symposium February 2009, Orlando, FL. 2009. [Abstract 7]."},{"key":"320_CR37","doi-asserted-by":"crossref","unstructured":"Scher HI, Fizazi K, Saad F, et al. Association of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 Affirm study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). European Society for Medical Oncology meeting, Vienna, Austria; September 28-October 2, 2012. This retrospective analysis of patients receiving enzalutamide in the AFFIRM trial identified that men receiving corticosteroids at baseline had a significantly worse survival than those who did not.","DOI":"10.1016\/S0923-7534(20)33514-6"},{"key":"320_CR38","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309\u201322.","journal-title":"Cell"},{"key":"320_CR39","doi-asserted-by":"crossref","unstructured":"Montgomery B, Kheoh T, Molina A, et al. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. 2014. doi: 10.1016\/j.eururo.2014.06.042 . This retrospective analysis of patients receiving abiraterone acetate in the COU-AA-301 trial identified that corticosteroids at baseline did not confer an independent prognostic impact on survival.","DOI":"10.1016\/j.eururo.2014.06.042"},{"key":"320_CR40","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.2012.45.4595","volume":"31","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Molina A, Li J, et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013;31:2791\u20138.","journal-title":"J Clin Oncol"},{"key":"320_CR41","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","volume":"332","author":"ME Taplin","year":"1995","unstructured":"Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393\u20138.","journal-title":"N Engl J Med"},{"key":"320_CR42","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2003.11.102","volume":"21","author":"ME Taplin","year":"2003","unstructured":"Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003;21:2673\u20138.","journal-title":"J Clin Oncol"},{"key":"320_CR43","first-page":"8712","volume":"61","author":"CY Chang","year":"2001","unstructured":"Chang CY, Walther PJ, McDonnell DP. Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res. 2001;61:8712\u20137.","journal-title":"Cancer Res"},{"key":"320_CR44","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/0008-5472.CAN-11-3980","volume":"72","author":"J Richards","year":"2012","unstructured":"Richards J, Lim AC, Hay CW, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012;72:2176\u201382.","journal-title":"Cancer Res"},{"key":"320_CR45","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-12-2350","volume":"73","author":"B Sahu","year":"2013","unstructured":"Sahu B, Laakso M, Pihlajamaa P, et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 2013;73:1570\u201380.","journal-title":"Cancer Res"},{"key":"320_CR46","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1056\/NEJMcibr1315706","volume":"370","author":"N Sharifi","year":"2014","unstructured":"Sharifi N. Steroid receptors aplenty in prostate cancer. N Engl J Med. 2014;370:970\u20131.","journal-title":"N Engl J Med"},{"key":"320_CR47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/annonc\/mds216","volume":"24","author":"TB Dorff","year":"2013","unstructured":"Dorff TB, Crawford ED. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol. 2013;24:31\u20138.","journal-title":"Ann Oncol"},{"key":"320_CR48","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1398-9995.1997.tb00968.x","volume":"52","author":"AG Oehling","year":"1997","unstructured":"Oehling AG, Akdis CA, Schapowal A, Blaser K, Schmitz M, Simon HU. Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy. 1997;52:144\u201354.","journal-title":"Allergy"},{"key":"320_CR49","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359\u201366.","journal-title":"JAMA"},{"key":"320_CR50","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448\u201356.","journal-title":"J Clin Oncol"},{"key":"320_CR51","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493\u2013500.","journal-title":"Cancer"},{"key":"320_CR52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813\u201322.","journal-title":"Lancet"},{"key":"320_CR53","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2223\/JPED.1773","volume":"84","author":"C Alves","year":"2008","unstructured":"Alves C, Robazzi TC, Mendonca M. Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr. 2008;84:192\u2013202.","journal-title":"J Pediatr"},{"key":"320_CR54","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(13)70424-8","volume":"14","author":"E Basch","year":"2013","unstructured":"Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013;14:1193\u20139.","journal-title":"Lancet Oncol"},{"key":"320_CR55","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"CJ Logothetis","year":"2012","unstructured":"Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13:1210\u20137.","journal-title":"Lancet Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0320-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-014-0320-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0320-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T15:11:37Z","timestamp":1717773097000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-014-0320-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1007\/s11864-014-0320-6","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]},"article-number":"6"}}